Trial reportLeukemia research2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Trial report in Leukemia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00946270 (A Phase II, Prospective, Open Label Study), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Leukemia · 2018Guideline
- In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.Journal of clinical pharmacology · 2018Trial
- Trial
- Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Haematologica · 2015Trial
- Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.Current hematologic malignancy reports · 2022Review
- New Markers of Disease Progression in Myelofibrosis.Cancers · 2021Review
- JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.Journal of immunotherapy and precision oncology · 2021Review
- The Rationale for Immunotherapy in Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2019Review
- Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.Hematology, transfusion and cell therapy · 2019Article
- An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.Clinical pharmacology in drug development · 2019Article
- Management of Myelofibrosis-Related Cytopenias.Current hematologic malignancy reports · 2018Review
- A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.Clinical pharmacology : advances and applications · 2018Article
- Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.Experimental and therapeutic medicine · 2017Article
- Pharmacotherapy of Myelofibrosis.Drugs · 2017Review
- Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.Clinical pharmacology : advances and applications · 2017Article
- Myelofibrosis: an update on drug therapy in 2016.Expert opinion on pharmacotherapy · 2016Review
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.Cancer chemotherapy and pharmacology · 2016Review
- Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.OncoTargets and therapy · 2016Review
- Population pharmacokinetics of pomalidomide.Journal of clinical pharmacology · 2015Article
- Profile of pomalidomide and its potential in the treatment of myelofibrosis.Therapeutics and clinical risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL). Patients (n = 29; 18 RBC-transfusion dependent) received 0.5mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.